Ozempic Is Science, Not Opinion

In this episode, I discuss why GLP 1 medications like Ozempic, Wegovy, Mounjaro, and ZepBound should be treated as science, not opinion. Through Melissa’s story, I explain how some patients are dismissed before they ever get a fair discussion about weight loss treatment. I also break down the evidence behind these medications, the prescribing challenges doctors face, and the access barriers that keep many eligible patients from receiving care. The episode closes with practical advice on how patients can ask better questions, seek second opinions, and find physicians who are prepared to support long term obesity treatment.Questions for Dr. Takem and the team💡 Start your journey today with Maryland Primary Care & WellnessBook your consultation: https://www.maryland-primarycare.com/